Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,720,610.98. The trade was a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Andrew Guggenhime also recently made the following trade(s):

• On Friday, October 18th, Andrew Guggenhime sold 42,000 shares of Vaxcyte stock. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00.

Vaxcyte Price Performance

PCVX stock traded up $0.46 during trading on Thursday, hitting $86.21. 1,196,122 shares of the stock traded hands, compared to its average volume of 910,039. The stock has a market cap of $10.74 billion, a price-to-earnings ratio of -18.74 and a beta of 0.94. Vaxcyte, Inc. has a 1 year low of $53.83 and a 1 year high of $121.06. The firm's 50 day moving average is $99.26 and its two-hundred day moving average is $92.03.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the business earned ($0.91) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Leerink Partners increased their target price on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Mizuho raised their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Jefferies Financial Group lifted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Finally, Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $147.50.

Institutional Investors Weigh In On Vaxcyte

Several large investors have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its position in Vaxcyte by 186.2% in the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after purchasing an additional 34,287 shares during the last quarter. Lord Abbett & CO. LLC raised its stake in Vaxcyte by 26.9% during the 3rd quarter. Lord Abbett & CO. LLC now owns 312,425 shares of the company's stock valued at $35,701,000 after purchasing an additional 66,183 shares during the period. Franklin Resources Inc. boosted its position in shares of Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock worth $315,162,000 after acquiring an additional 324,560 shares during the last quarter. Sanctuary Advisors LLC bought a new position in shares of Vaxcyte during the 3rd quarter valued at about $507,000. Finally, Virtu Financial LLC purchased a new position in Vaxcyte during the 3rd quarter valued at approximately $355,000. 96.78% of the stock is currently owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.